Sign in
CompletedNo phase

Efficacy of Probiotic Lactobacillus Crispatus M247 in Promoting High-risk Human Papillomavirus (HR-HPV) Infection Clearance and Modifying Vaginal Microbiota

Key facts

Who runs it
Liaquat University of Medical & Health Sciences
Where
Italy3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
66 people enrolled
Started
5 Jan 2022
Ended
30 Dec 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Lactobacillus crispatus M247 (Crispact®)
  • Placebo
Record updated
4 June 2025

Who can take part

Age
18 years to 69 years
Sex
Women only
Healthy volunteers
Cannot take part
Show the full registry criteria (12)Hide the full registry criteria

Who can take part

  • Women aged 18-69 years
  • First diagnosis of HR-HPV infection via DNA-HPV screening
  • Cytology results showing ASC-US or LSIL
  • Negative colposcopy or biopsy (absence of lesions)
  • Ability to provide written informed consent

Who cannot take part

  • Prior HPV vaccination
  • Current treatment with antibiotics, immunomodulatory, or immunosuppressive therapies
  • History of cervical treatments for pre-neoplastic pathology
  • Diagnosed immune system or neoplastic diseases requiring chemotherapy
  • Known hypersensitivity to product components
  • Cytology showing HSIL (High-Grade Squamous Intraepithelial Lesion) requiring treatment
  • Pregnancy, lactation, or planning to become pregnant within 6 months

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This clinical trial evaluates the efficacy of the probiotic strain Lactobacillus crispatus M247 in promoting the clearance of genital high-risk human papillomavirus (HR-HPV) infection and restoring the balance of the vaginal microbiota. The study adopts a multicenter, randomized, single-blind, longitudinal, prospective design involving HR-HPV-positive patients. Primary outcomes include HR-HPV clearance rates and microbiota composition changes.

The 2 groups in the trial

  • Probiotic supplement Lactobacillus crispatus M247 groupTreatment being tested

    Participants in this group will receive probiotic supplement Lactobacillus crispatus M247 (Crispact®) in stick form, administered orally at a dose of one stick per day for 4 months. Each stick contains 20 billion CFU of L. crispatus M247.

    Treatment: Lactobacillus crispatus M247 (Crispact®)

  • Control GroupPlacebo, for comparison

    Participants in the control group will receive a placebo identical in appearance and packaging to the experimental product, administered orally at a dose of one stick per day for 4 months.

    Treatment: Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluation of the Efficacy of Lactobacillus Crispatus M247 Administration in Promoting Clearance of Genital HR-HPV Infection and Modulating the Vaginal Microbiota: A Multicenter, Randomized, Placebo-Controlled, Single-Blind, Longitudinal, Prospective Clinical Trial
Record updated
4 June 2025